Selected article for: "animal range and disease severity"
Author: Fierabracci, Alessandra; Arena, Andrea; Rossi, Paolo
Title: COVID-19: A Review on Diagnosis, Treatment, and Prophylaxis
  • Cord-id: 85i9rkwq
  • Document date: 2020_7_21
    • ID: 85i9rkwq
    Snippet: Coronavirus 2 (CoV) Severe Acute Respiratory Syndrome (SARS-CoV2) is causing a highly infectious pandemic pneumonia. Coronaviruses are positive sense single-stranded RNA viruses that infect several animal species, causing symptoms that range from those similar to the common cold to severe respiratory syndrome. The Angiotensin Converting Enzyme 2 (ACE2) is the SARS-CoV2 functional receptor. Measures are currently undertaken worldwide to control the infection to avoid disruption of the social and
    Document: Coronavirus 2 (CoV) Severe Acute Respiratory Syndrome (SARS-CoV2) is causing a highly infectious pandemic pneumonia. Coronaviruses are positive sense single-stranded RNA viruses that infect several animal species, causing symptoms that range from those similar to the common cold to severe respiratory syndrome. The Angiotensin Converting Enzyme 2 (ACE2) is the SARS-CoV2 functional receptor. Measures are currently undertaken worldwide to control the infection to avoid disruption of the social and economic equilibrium, especially in countries with poor healthcare resources. In a guarded optimistic view, we hope that the undertaken preventive and treatment measures will at least contribute to contain viral diffusion, attenuate activity, or even eliminate SARS-CoV2. In this review, we discuss emerging perspectives for prevention/treatment of COVID-19 infection. In addition to vaccines under development, passive immunization is an open opportunity since patients develop neutralizing antibodies. A full spectrum of potential drugs for COVID-19 infections could in turn affect virus binding or enzymatic activities involved in viral replication and transcription. Furthermore, clinical trials are currently evaluating the safety and efficacy of anti-inflammatory drugs, such as tocilizumab. Bioinformatics may allow characterization of specific CD8+ and CD4+ T cell responses; thus, CoV2 T cells’ frequency can be correlated with the disease severity and outcome. Combinatorial antibody phage display may be empowered to identify the immune repertoire of CoV2-specific neutralizing antibodies.

    Search related documents:
    Co phrase search for related documents
    • absence presence and acid vaccine: 1
    • absence presence and activity attenuate: 1
    • absence presence and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • absence presence and acute respiratory disease syndrome: 1, 2, 3, 4, 5, 6
    • absence presence and live vaccine: 1
    • absence presence and long term treatment: 1, 2
    • absence presence and lopinavir ritonavir: 1, 2
    • absence presence and low molecular weight heparin: 1
    • absence presence and lung damage: 1, 2
    • absence presence and lupus erythematosus: 1
    • absence presence and lymphocyte count: 1, 2, 3, 4, 5, 6
    • absence presence and macaque model: 1, 2
    • acceptable safety and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acceptable safety and acute respiratory disease syndrome: 1
    • acceptable safety and live vaccine: 1
    • acceptable safety and lopinavir hydroxychloroquine: 1
    • acceptable safety and lopinavir ritonavir: 1, 2
    • acceptable safety and lung damage: 1
    • acceptable safety and lupus erythematosus: 1